DIA Biosimilars 2013

Omeros

Omeros’ OMS302 moves to phase III

Tuesday, March 29, 2011 01:02 PM

Seattle-based biotech Omeros, said its experimental treatment for patients undergoing eye surgery to correct cataracts was safe, able to maintain pupil dilation during the procedure, and reduce postoperative pain and irritation. The results—which Omeros said will be published and presented later in a scientific forum—were from a study of 221 patients that randomly assigned people to a control group, the Omeros combination product, or its two individual components. Based on the results, the company plans to take the drug, OMS302, into phase III clinical trials.

More... »

Cenduit: Now with Patient Reminders
CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs